Takeda, UCL Launch Neurodegenerative Collaboration

Takeda Pharmaceutical and University College London (UCL) said today they have launched a new research collaboration intended to identify and validate new gene targets for treating neurodegenerative disease. The value of the collaboration was not disclosed. UCL and Takeda said their partnership will focus on developing mechanistic approaches to identify genes or signaling pathways that modify neurodegenerative disease processes affecting neuronal health—citing as examples ALS, Huntington’s disease, and Parkinson’s disease. Takeda and UCL researchers will work together across preclinical drug discovery areas that include bioinformatics, molecular biology, and pharmacology. Tetsuyuki Maruyama, Ph.D., general manager of Takeda’s Pharmaceutical Research Division, noted in a statement that central nervous system diseases is one of Takeda’s core therapeutic areas, along with cardiovascular and metabolic disorders, oncology, immunology and respiratory diseases, general medicine, and vaccines.…


Link to Full Article: Takeda, UCL Launch Neurodegenerative Collaboration